Brief: Sensorion FY IFRS Net Loss Widens To 12.4 Million Euros

Sensorion SA

27/03/2019 06:36

March 27 (Reuters) - SENSORION SA  ALSEN.PA :
    * SENSORION REPORTS ITS 2018 ANNUAL RESULTS; 75% OF PATIENTS
ENROLLED IN THE SENS-111 CLINICAL TRIAL
    * EUR 2.7M IN CASH AT 31 DECEMBER 2018 AND A BOND ISSUE
OFFERING
COMPANY GROSS INCOME OF EUR 4.7M ON 11 MARCH 2019
    * FY IFRS OPERATING LOSS EUR 12.2 MILLION VERSUS LOSS EUR
9.5
MILLION YEAR AGO
    * FY IFRS NET LOSS EUR 12.4 MILLION VERSUS LOSS EUR 9.7
MILLION
YEAR AGO
    * TOTAL EQUITY CAME TO EUR 3.5M AT 31 DECEMBER 2018 VERSUS
EUR
7.4M AT 31 DECEMBER 2017
    * RESULTS OF PHASE 2 TRIAL ON EFFICACY OF SENS-111 IN ACUTE
UNILATERAL VESTIBULOPATHY ARE EXPECTED DURING SECOND HALF OF
2019
    * PHASE 2 OF SENS-401, IN SUDDEN HEARING LOSS (SSNHL), IS
COMMENCING WITH INTERMEDIARY RESULTS EXPECTED AT END OF YEAR
    * FY IFRS OPERATING INCOME EUR 2.3 MILLION VERSUS LOSS EUR
2.0
MILLION YEAR AGO

Source text for Eikon:  ID:nBw3M3yYBa 
Further company coverage:  ALSEN.PA 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))